argenx SE
summary the safety profile observed during long term treatment with in adapt mirrored that seen during adapt even while being conducted during the covid global pandemic this analysis suggests that long term treatment with is efficacious providing consistent and repeatable clinically meaningful improvement in function and strength while remaining well tolerated adapt is a planned year study and is currently ongoing | argenx SE
Company
Deck Type
Deck date
April 2022
Slide
10 of 10
Related slides by other companies
Investor Presentation
October 2020
SPAC
June 2021
Investor Presentation
April 2021
IPO
October 2020
Other recent decks by argenx SE
Results
February 2024
Investor Conference
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io